Valuation: Sunho Biologics, Inc.

Market Cap 906M 1.05B 134M 117M 109M 99.66M 188M 12.81B 191M 1.28B 502M 6.38B 504M 493M 21.38B P/E 2023 *
-
P/E 2024 -5.67x
Enterprise Value 490M 569M 72.55M 63.07M 58.7M 53.9M 102M 6.93B 103M 692M 272M 3.45B 272M 266M 11.56B EV / Sales 2023 *
-
EV / Sales 2024 3,059x
Free-Float
32.45%
Yield 2023 *
-
Yield 2024 -
6 months+2.73%
Current year-3.77%
Current year 5.49
Extreme 5.49
8
1 year 5.49
Extreme 5.49
8.6
3 years 3
Extreme 3
15.42
5 years 3
Extreme 3
15.42
10 years 3
Extreme 3
15.42
Manager TitleAgeSince
Chief Executive Officer 44 2026-01-22
Director of Finance/CFO 47 2023-07-21
Corporate Secretary 35 2023-07-21
Director TitleAgeSince
Chairman 53 2023-07-21
Director/Board Member 44 2023-07-20
Director/Board Member 52 2023-07-21
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--%-9.75% - 124M
+1.25%+1.47%+0.35%+15.84% 48.53B
-2.41%-0.90%+411.96%+472.09% 39.87B
-1.16%+12.96%+28.81%+7.27% 38.68B
-1.88%-3.03%+5.69%+66.52% 35.13B
-1.74%+5.12%+14.44%+44.64% 29.79B
-0.21%-4.04%+36.40%+126.06% 16.11B
-2.85%-3.92% - - 16.08B
+1.00%+2.72%+3.31%+16.75% 13.61B
-1.19%-1.32%-1.73%-34.97% 12.62B
Average -0.78%+0.93%+54.39%+89.27% 25.05B
Weighted average by Cap. -0.79%+2.03%+80.16%+108.20%

Financials

2023 2024
Net sales 17.53M 20.36M 2.6M 2.26M 2.1M 1.93M 3.64M 248M 3.7M 24.76M 9.72M 123M 9.75M 9.53M 414M 38K 44.11K 5.63K 4.89K 4.55K 4.18K 7.89K 537K 8.01K 53.65K 21.06K 267K 21.13K 20.66K 896K
Net income -133M -154M -19.65M -17.08M -15.9M -14.59M -27.56M -1.88B -27.99M -187M -73.54M -934M -73.78M -72.16M -3.13B -79.96M -92.83M -11.84M -10.29M -9.58M -8.79M -16.61M -1.13B -16.86M -113M -44.31M -563M -44.46M -43.48M -1.89B
Net Debt -201M -233M -29.76M -25.87M -24.08M -22.1M -41.74M -2.84B -42.39M -284M -111M -1.41B -112M -109M -4.74B -416M -483M -61.6M -53.55M -49.84M -45.76M -86.42M -5.88B -87.75M -588M -231M -2.93B -231M -226M -9.82B
Logo Sunho Biologics, Inc.
Sunho Biologics Inc is a company mainly engaged in the research, development and production of biotechnology. The Company is primarily engaged in the discovery, development and commercialization of biologics that modulate the immune microenvironment by directly modulating the innate and adaptive immune systems. The Company has three core products, namely IAH0968, IAP0971 and IAE0972. IAH0968 is an antibody-dependent cell-mediated cytotoxicity-enhancing monoclonal antibody. IAP0971 and IAE0972 are both antibody cytokines.
Employees
-
  1. Stock Market
  2. Stocks
  3. 2898 Stock